Company* |
Product |
Description |
Indication |
Status (Date) |
| ||||
AUTOIMMUNE | ||||
Virogenomics Inc.* |
VG1000 |
Designed to target T cells that cause inflam- mation and myelin damage in the brain and spinal cord |
Multiple sclerosis |
FDA granted orphan drug status to VG1000 (5/13) |
|
||||
CANCER | ||||
Corixa Corp. (CRXA) |
Bexxar |
A radioimmunotherapy; tositumomab and iodine-131 tositumomab |
Non-Hodgkin's lymphoma |
FDA is delaying action up to three months on the BLA (5/5) |
|
||||
Millennium Pharmaceuticals Inc. (MLNM) |
Velcade |
Bortezomib; proteasome inhibitor |
Multiple myeloma |
FDA granted approval (5/14) |
|
||||
SuperGen Inc. (SUPG) |
Dacogen |
Decitabine; inhibits DNA methyltransferase activity |
Advanced-stage myelodysplastic syndrome |
FDA designated Dacogen a fast-track product (5/12) |
|
||||
INFECTION | ||||
Agouron Pharmaceuticals Inc.* |
Viracept (FDA-approved) |
Nelfinavir mesylate; a proteas inhibitor |
HIV |
FDA approved a 625-mg formulation of Viracept (5/1) |
|
||||
MISCELLANEOUS | ||||
Genentech Inc. (NYSE:DNA) |
Xolair |
Omalizumab; anti-IgE therapy; a humanized monoclonal antibody |
Allergic asthma |
An FDA advisory panel recommended approval of Xolair (5/15) |
|
||||
Unigene Laboratories Inc. (OTC BB:UGNE) |
Fortical |
A nasal calcitonin product |
Osteoporosis |
FDA accepted the NDA for review (5/5) |
| ||||
Notes: | ||||
* Privately held | ||||
Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market. | ||||
NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board. |